The incidence of acute coronary occlusions after percutaneous transluminal coronary angioplasty is reduced by intracoronary application of dipyridamole - A prospective randomized trial;Dipyridamol intrakoronar reduziert die inzidenz des akuten koronargefassverschlusses bei der perkutanen transluminalen koronarangioplastie - Eine prospektiv randomisierte untersuchung

Zeitschrift fur Kardiologie

Volumn 86, Issue 12, 1997, Pages 961-967

  Heintzen, M P ^a   Heidland, U E ^a   Klimek, W J ^a   Michel, C J ^a   Keim, M ^a   Leschke, M ^a   Schwartzkopff, B ^a   Vester, E G ^a   Strauer, B E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Abrupt vessel closure; Coronary perfusion; Dipyridamole; Platelet aggregation; PTCA

Indexed keywords

DIPYRIDAMOLE; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ARTERY BYPASS; CORONARY CIRCULATION; CORONARY DISEASE; CORONARY THROMBOSIS; CORONARY VESSELS; DIPYRIDAMOLE; FEMALE; HEPARIN; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREMEDICATION; PROSPECTIVE STUDIES; RECURRENCE; VASODILATION; VASODILATOR AGENTS;

EID: 0031469670     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920050137     Document Type: Article

References (30)

1. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld J\V (1987) Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76:125-134
2. Buchanan MR, Rosenfeld J, Gent M, Lawrence W, Hirsh J (1979) Increased dipyridamole plasma concentrations associated with salicylate administration: relationship to effects on platelet aggregation in vivo. Thromb Res 15:813-820
3. Chesler E, Gornick C, Pierpont G, Weir K (1989) High incidence of acute coronary occlusions complicating percutaneous transluminal coronary angioplasty for Xangina pectoris. Am J Cardiol 15:665-667
4. Danchin N, Juilliere Y, Kettani C, Buffet P, Anconina J, Cuilliere M, Cherrier F (1994) Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J 127:494-498
5. Dawicki DD, Agarwal KC, Parks RE (1985) Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 34: 3965-3972
6. Detre KM, Holmes DR, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio MG, Kent KM, Myler RK (1990) Incidence and consequences of periprocedural occlusion: The 1985-1986 National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 82:739-750
7. Ellis SG, Vandormael MG, Cowley MJ, Di Sciascio G, Deligonul U, Topol EJ, Bulle TM (1990). Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patients selection. Circulation 82:1193-1202
8. Emmons PR, Harrison MJG, Honour AJ, Mitchell JRA (1965) Effect of dipyridamole on human platelet behaviour. Lancet 2:603-606
9. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L (1994) Characterization of relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 23:1562-1569
10. Feyter de PJ, van den Brand M, Jaarman GJ, van Domburg R, Serruys PW, Suryapranata H (199I) Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Circulation 83:927-936
11. Feyter de PJ, Serruys PW, vd Brand M, Hugenholtz PG (1991) Percutaneous transluminal coronary angioplasty for unstable angina. Am J Cardiol 68:125B-135B
12. Fitzgerald GA (1987) Drug therapy: Dipyridamole. New Engl J Med 316:1247-1257
13. German DC, Kredich NM, Bjomsson TD (1989) Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 45:80-84
14. Haslam RJ, Lynham JA (1972) Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloradenosine. Life Sci 11:Part 2:1143-1154
15. Heintzen MP, Motz W, Leschke M, Körholz NP, Schulthei HP, Horstkotte D, Schmitt HH, Vester EG, Preue CJ, Schulte HD, Strauer BE (1994) Akuter Koronargefäßverschluß nach elektiver perkutaner transluminaler Koronarangioplastie: Inzidenz und Therapie bei 5000 konsekutiven Patienten. Dtsch Med Wschr 119:1023-1028
16. Heintzen MP, Motz W, Leschke M, Schultheiß HP, Horstkotte D, Vester E, Wahbe L, Ries T, Pütz H, Sommer P, Pels K, Schulte HD, Strauer BE (1994) PTCA im Stadium des akuten Myokardinfarktes: Hospitalverlauf von 785 konsekutiven Patienten. Z Kardiol 83:404-413
17. Kubier W, Spieckermann PG, Bretschneider HJ (1970) Influence of dipyridamole (Persantin) on myocardial adenosine metabolism. J Mol Cell Cardiol 1:23
18. Kubier W (1971) Die Bindung des Koronardilatators Dipyridamol an die Plasmaeiweißkörper des Menschen. Arch Kreislaufforschung 64:115
19. Lembo NJ, Black AJR, Roubin GS, Wilentz JR, Mufson LH, Douglas JS, King SB (1990) Effect of pretreatment with aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary ancioplasty. Am J Cardiol 65:422-426
20. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ (1992) Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographie and therapeutic profile. J Am Coll Cardiol 19:926-935
21. Mabin TA, Holmes DR, Smith HC, Vlietstra RE, Bove AA, Reeder GS, Chesebro JH, Bresnahan JF, Orszulak TH (1985) Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary ansioplasty. J Am Coll Cardiol 5:198-202
22. Merino A, Cohen M, Badimon JJ, Fuster V (1994) Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol 24:1091-1094
23. Mills DCB (1982) The role of cyclic nucleotides in platelets. In: Kebabian JW, Nathanson JA (eds) Cyclic nucleotides: Part II: physiology and pharmacology. Springer Verlag, Berlin, pp 723-761
24. Moncada S, Korbut R (1978) Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1: 1286-1289
25. Olsson RA, Pearson JD (1990) Cardiovascular purinoceptors. Physiological Reviews 70:761-845
26. Schächinger V, Zeiher AM (1995) Neue Aspekte der gerinnungshemmenden Therapie im Rahmen der perkutanen transluminalen koronaren Angioplastie. Z Kardiol 84:651-667
27. Schrader J, Berne RM, Rubio T (1972) Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 223:159
28. Stein B, Fuster V, Israel DH, Cohen M, Badimon L, Badimon JJ, Chesebro JH (1989) Platelet inhibitor agents in cardiovascular disease: An update. J Am Coll Cardiol 14:813-836
29. Strauer BE, Heidland UE, Vogt M, Schwartzkopff B, Heintzen MP (1995) Protektion und Preconditioning" des menschlichen Herzens während perkutaner transluminaler Koronarangioplastie (PTCA) durch Dipyridamol intrakoronar. Med Klinik 90:125-130
30. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B (1996) Pharmacologie myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 28:1119-1126